Research statistics
Survodutide research: publications and trials
At a glance
Publications, all years
71
Since 2022
Publications in 2026 so far
31
Through November 15, 2026
Human clinical research
26.8%
19 of 71 classified
Registered clinical trials
35
ClinicalTrials.gov
Randomized controlled trials
12
Publications reporting an RCT in people
Systematic reviews and meta-analyses
11
Preclinical studies
9.9%
5 animal · 2 in vitro · 0 computational
Records that only mention it
18
Not counted above
Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Survodutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2022 | 0 | 1 | 0 | 0 | 1 |
| 2023 | 3 | 0 | 1 | 0 | 4 |
| 2024 | 3 | 1 | 7 | 3 | 14 |
| 2025 | 4 | 1 | 13 | 3 | 21 |
| 2026 (to date) | 9 | 4 | 16 | 2 | 31 |
Study types
| Review | 26 |
|---|---|
| Randomized controlled trial | 12 |
| Editorial, letter or other | 8 |
| Meta-analysis | 7 |
| Animal study | 5 |
| Other clinical trial | 5 |
| Systematic review | 4 |
| In vitro study | 2 |
| Observational human study | 2 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 57 |
|---|---|
| Obesity and weight management | 41 |
| Gastrointestinal | 22 |
| Endocrinology | 19 |
| Cardiovascular | 8 |
| Reproductive and sexual health | 2 |
| Neurological and mental health | 1 |
Registered clinical trials
10 of 18 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 25 · Not yet recruiting: 4 · Active, not recruiting: 3 · Recruiting: 3
Phase 1: 19 · Phase 2: 4 · Phase 3: 12
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access
PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · September 29, 2026 · Meta-analysis · cited 0 times · open access
PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses
- Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
Diabetes, obesity & metabolism · October 8, 2025 · Meta-analysis · cited 5 times
PMID 41063381 · DOI 10.1111/dom.70187 · Reviews and meta-analyses
- Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
Diabetes, obesity & metabolism · September 8, 2025 · Meta-analysis · cited 2 times
PMID 40922121 · DOI 10.1111/dom.70105 · Reviews and meta-analyses
- Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
The Journal of clinical endocrinology and metabolism · September 1, 2025 · Meta-analysis · cited 45 times
PMID 40489581 · DOI 10.1210/clinem/dgaf336 · Reviews and meta-analyses
- Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · April 1, 2025 · Meta-analysis · cited 3 times · open access
PMID 40557198 · DOI 10.1080/08998280.2025.2480512 · Reviews and meta-analyses
- Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.
Diabetology & metabolic syndrome · November 6, 2024 · Meta-analysis · cited 8 times · open access
PMID 39508238 · DOI 10.1186/s13098-024-01501-x · Reviews and meta-analyses
- Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
Journal of translational medicine · May 26, 2026 · Systematic review · cited 0 times · open access
PMID 42192439 · DOI 10.1186/s12967-026-08219-6 · Reviews and meta-analyses
- Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Endocrinology, diabetes & metabolism · January 1, 2026 · Systematic review · cited 2 times · open access
PMID 41466530 · DOI 10.1002/edm2.70157 · Reviews and meta-analyses
- Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
Obesity (Silver Spring, Md.) · July 20, 2025 · Systematic review · cited 19 times · open access
PMID 40685589 · DOI 10.1002/oby.24360 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
The New England journal of medicine · June 7, 2024 · Randomized controlled trial · cited 515 times · open access
PMID 38847460 · DOI 10.1056/nejmoa2401755 · Human clinical research
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
The lancet. Diabetes & endocrinology · February 5, 2024 · Randomized controlled trial · cited 232 times
PMID 38330987 · DOI 10.1016/s2213-8587(23)00356-x · Human clinical research
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
Molecular metabolism · November 7, 2022 · Animal study · cited 147 times · open access
PMID 36356832 · DOI 10.1016/j.molmet.2022.101633 · Animal studies
- Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia · December 14, 2023 · Randomized controlled trial · cited 138 times · open access
PMID 38095657 · DOI 10.1007/s00125-023-06053-9 · Human clinical research
- Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
The Journal of clinical investigation · July 1, 2025 · Review · cited 73 times · open access
PMID 40590228 · DOI 10.1172/jci186425 · Reviews and meta-analyses
Latest publications
- Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England) · November 9, 2026 · Randomized controlled trial · cited 0 times
PMID 43003106 · DOI 10.1016/s0140-6736(26)02140-9 · Human clinical research
- GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access
PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses
- Charcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides.
The AAPS journal · October 30, 2026 · In vitro study · cited 0 times
PMID 42963450 · DOI 10.1208/s12248-026-01311-1 · In vitro studies
- Interpreting Survodutide Renoprotection in a Hyperfiltration Model.
Diabetes, obesity & metabolism · October 19, 2026 · Editorial, letter or other · cited 0 times
PMID 42897119 · DOI 10.1111/dom.71467 · Commentary and other
- From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.
Frontiers in pharmacology · October 13, 2026 · Review · cited 0 times · open access
PMID 42947668 · DOI 10.3389/fphar.2026.1784959 · Reviews and meta-analyses
- Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?
Diabetes, obesity & metabolism · October 12, 2026 · Editorial, letter or other · cited 0 times · open access
PMID 42864267 · DOI 10.1111/dom.71446 · Commentary and other
- The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.
Obesity reviews : an official journal of the International Association for the Study of Obesity · October 11, 2026 · Review · cited 0 times · open access
PMID 42860310 · DOI 10.1111/obr.70228 · Reviews and meta-analyses
- Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Contemporary clinical trials · October 2, 2026 · Review · cited 0 times
PMID 42822760 · DOI 10.1016/j.cct.2026.108493 · Reviews and meta-analyses
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
The New England journal of medicine · October 1, 2026 · Randomized controlled trial · cited 0 times
PMID 42820639 · DOI 10.1056/nejmoa2607219 · Human clinical research
- Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Diabetes, obesity & metabolism · October 1, 2026 · Animal study · cited 2 times · open access
PMID 42823075 · DOI 10.1111/dom.71387 · Animal studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: BI 456906; Survodutide
((TITLE_ABS:"BI 456906" OR CHEM:"BI 456906" OR TITLE_ABS:"BI456906" OR CHEM:"BI456906") OR (TITLE_ABS:"Survodutide" OR CHEM:"Survodutide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Survodutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/survodutide